Jill Milne
Founder bei ASTRIA THERAPEUTICS, INC.
Vermögen: 61 606 $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ken Bate | M | 73 | 10 Jahre | |
Andrea Matthews | F | - | 10 Jahre | |
Noah Clauser | M | 51 | 13 Jahre | |
Gregg Lapointe | M | 65 | 5 Jahre | |
Michael Kishbauch | M | 75 | 8 Jahre | |
Jonathan Violin | M | 49 | 3 Jahre | |
Hugh Cole | M | 59 | 5 Jahre | |
Joanne Beck | M | 63 | 5 Jahre | |
Frederick Callori | M | 56 | 3 Jahre | |
Alan Levin | M | 62 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 21 Jahre |
Ben Harshbarger | M | 55 | 4 Jahre | |
Christopher J Morabito | M | - | 2 Jahre | |
Andrew Komjathy | M | 61 | 5 Jahre | |
Keri McGrail | F | - | 3 Jahre | |
John Ruesch | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Deirdre Cunnane | F | 59 | 4 Jahre | |
Michael R. Jirousek | M | 65 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 7 Jahre |
Christoph H. Westphal | M | 56 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 6 Jahre |
Ron Laufer | M | 57 | - | |
Jean George | F | 66 | 9 Jahre | |
Ian Crocker Sanderson | M | 63 | 3 Jahre | |
Peter Elliott | M | 64 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
David Sinclair | M | 55 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Richard H. Aldrich | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Nicholas G. Galakatos | M | 66 | - | |
Burt Adelman | M | 71 | 5 Jahre | |
Paul Schimmel | M | 83 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Michael Ross | M | 75 | 9 Jahre | |
Richard Pops | M | 62 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Erin M. Duffy | M | 55 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | - |
Claude Bertrand | M | 61 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | - |
Angelika Fretzen | M | - | 5 Jahre | |
Steven E. Shoelson | M | - | - | |
Roger Xie | M | 54 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 3 Jahre |
Jean Bemis | F | - | - | |
Jeffrey Ives | M | 72 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 6 Jahre |
Annette Doherty | M | - |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 5 Jahre |
Jennifer Tjernagel | F | - |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 9 Jahre |
Edward Dulac | M | 49 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 4 Jahre |
Lucienne Ronco | F | - | - | |
Joanne Donovan | M | 67 | 10 Jahre | |
Brian Shin | M | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 2 Jahre |
Henry Rath | M | 53 | - | |
Jennifer M. Cermak | M | 51 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 5 Jahre |
John C. Roberts | M | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
James L. Ellis | M | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Leigh Bonney | F | 66 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 12 Jahre |
Catherine Knupp | M | 63 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 4 Jahre |
Laura A. Egnash | F | - |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 7 Jahre |
Andrew Nichols | M | 63 | 9 Jahre | |
Rick Modi | M | 55 | 2 Jahre | |
Joseph Johnston | M | - | - | |
Chris Stevens | M | 65 | 1 Jahre | |
David Sinclair | M | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 6 Jahre |
John R. Kirk | M | 67 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 2 Jahre |
Suzanne Ronnholm | F | - |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Michael S. Curtis | M | - | - | |
Stephen J. Hoffman | M | 70 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Jeffrey Capello | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
John Freund | M | 70 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Alan Krasner | M | 60 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 6 Jahre |
Mostafa Analoui | M | 63 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 7 Jahre |
Michael D. Wider | M | - |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 4 Jahre |
John Clarke | M | 70 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Wilfred Jaeger | M | 67 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 3 Jahre |
Stephen D. Chubb | M | 80 | 7 Jahre | |
Roger S. Newton | M | 73 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 4 Jahre |
Charles Bisgaier | M | 71 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 2 Jahre |
Craig Saxton | M | 81 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 8 Jahre |
John LaMattina | M | 74 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 6 Jahre |
James Bristol | M | 77 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 4 Jahre |
John F. Bender | M | 75 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 20 Jahre |
Christopher Z. Thomajan | M | - | 4 Jahre | |
Paul Aldridge | M | - |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 12 Jahre |
Howard L. Foyt | M | 69 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 5 Jahre |
R. Wayne Frost | M | 69 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 7 Jahre |
Michael Varney | M | 65 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 5 Jahre |
Paul Brannelly | M | 51 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Garen Bohlin | M | 76 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 3 Jahre |
Stephen Kraus | M | 47 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 2 Jahre |
Andrew Perlman | M | 49 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 1 Jahre |
Anna E. Crivici | M | - |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | 2 Jahre |
Ted Hibben | M | 65 | 3 Jahre | |
Maria C. Mancini | F | - | 9 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 84 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jill Milne
- Persönliches Netzwerk